FTC Weighs In on Orange Book Listing of Drug-Device Patents

On March 22, 2024, the Federal Trade Commission ("FTC") filed an amicus brief in Teva Branded Pharmaceutical Products R&D, et al. v. Amneal Pharmaceuticals of New York, LLC, et al.,...

Related Keywords

Robert Califf , Amneal Pharmaceuticals Of New York , Us District Court , Jones Day , Drug Administration , House Oversight Committee , Federal Trade Commission , New York , New Jersey , Orange Book , Drug Products , Therapeutic Equivalence , Hatch Waxman Act , New Drug Application , New Drug , Patent Submission , Listing Requirements , Month Stays , Abbreviated New Drug Applications Certifying That , Patent Claiming , Drug Is Invalid , Will Not Be Infringed , Orange Book Transparency Act , Abbreviated New Drug Application ,